All-Share Deal Gives Red Light Shareholders 70% Control
On March 10, 2026, Red Light Holland Corp. (CSE: TRIP) announced a definitive agreement to acquire Filament Health Corp. (OTC: FLHLF) through an all-share statutory plan of arrangement. The transaction structure will result in existing Red Light Holland shareholders retaining an estimated 70% ownership of the newly combined entity. This move consolidates two key players in the emerging psychedelic medicine industry, merging Red Light's consumer brand and production scale with Filament's pharmaceutical research and development foundation.
Acquisition Unlocks 76 Patents and Licensed Manufacturing
The transaction significantly expands Red Light Holland's drug development platform by incorporating Filament Health's valuable assets. Central to the deal are 76 issued patents covering the extraction, purification, and formulation of natural psilocybin. Red Light also gains Filament's GMP-compliant manufacturing facility in Vancouver, which holds a Health Canada Level 8 Controlled Substances Dealer's Licence. This integration provides the infrastructure for producing pharmaceutical-grade psilocybin, including Filament's patented PEX010 botanical drug candidate, for use in its Health Canada and FDA-authorized clinical programs.
Merger Aims for Commercialization and Capital Efficiency
The strategic rationale for the acquisition centers on creating a vertically integrated psychedelic company positioned for future commercialization. Leadership from both companies state the merger is expected to streamline operations, consolidate teams, and improve capital efficiency. By combining Filament's clinical research capabilities with Red Light's real-world microdosing data and mass production experience, the new entity aims to accelerate the development of patented psilocybin drug candidates. The company is now better positioned to target jurisdictions with emerging regulatory pathways for clinical supply, compassionate use programs, and other authorized distribution channels.
